The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Afternoon AS
Absolutely the £4m contract is a RSV Contract and not a Covid Hunan Challenge Studies.He has not quoted an exact price on these as this is commercially sensitive.
When you selling something truly unique you want to have individual negotiations and not give a benchmark which subsequent Company’s can quote.
I understand your point, my view is that they needed the Quotient machine to aid the Covid challenge studies, they must test candidates for antibodies and have they had it etc Pre study, and of course they will need to carry out intense testing on candidates during and after vaccination. I think CF as an entrepreneur saw a money generating opportunity with this machine also. Gotta hand it to the guy really.
Lucky, perhaps you ought to check your own facts first. The two contracts, including the £4M contract are not one of the 10 covid challenge trials whick will attract circa £10M a piece
Totally agree KTRB, however it makes me read more into Cathal's statements. Going back 3 months this revenue stream was going to be huge, they could get another machine if necessary....etc......Reality was that the testing didnt start until at least a month after the machine was installed, so the small window of opportunity was even smaller.
Then he moved on to the "we have 10 potential challenge studies at £8m each" mantra which is now 2 contracts with one of them for £4M in Q4.
I know it's his job to sell the vision, I just prefer to work with facts.
Testing is yesterdays investment, there is a new test being released every day it seems. The market is flooded with them. The future is a vaccine and the only way to expedite the process sits within Open Orphan. In my opinion of course.
Accuracy and repeatability of finger prick tests are improving - see attached.
https://www.imperial.ac.uk/news/200713/biggest-study-antibody-fingerprick-tests-identifies/
The Fortress test was deemed good enough to provide the data for a nationwide study rather than use the lab test which takes too long . not viable for such a study.
Window of opportunity was always going to be limited.......